3/ 💡 The new functional test (IcAR-PD1 assay) demonstrates remarkable sensitivity and specificity in assessing ligand activity. It surpasses traditional methods like PDL1 staining, providing a comprehensive evaluation of ligand function also in FFPE tissues!

Pan-KRAS probe compounds BI-2865 and BI-2493 active against a broad range of oncogenic #KRAS variants that selectively inactivate downstream signaling and tumor growth, while sparing NRAS and HRAS. Now in print nature #openaccess #precisiononcology nature.com/articles/s4158…

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the TAPUR Study Journal of Clinical Oncology doi.org/10.1200/JCO.23… 👉efficacy, but only moderate association btw TMB and ORR, PFS, & OS 👉TMB alone is insufficient to predict benefit from ICIs ESMO - Eur. Oncology

Accumulative publications showing that immunotherapy is more potent when given early in the day. Time to change our practice and give our IOs in the morning? At least until evidence of a circadian biology supporting the hypothesis & availability of data from phase III trials?

Online now: Targeting innate immune pathways for cancer immunotherapy dlvr.it/Sw0KnP

Writing

Un tipo q triplico el dolar. Y con un 140 de inflacion es candidato a presidente y encima apura al otro candidato. DE NO CREER

Q pesado Massa. Le esta haciendo un reportaje. NI UNA PROPUESTA. El ministro de economia q nos termino de fundir

La politica cada día me da más asco.

Por momentos vergüenza ajena. Pero la mayor parte del tiempo una angustia fuerte!

We close Wellcome Connecting Science Learning and Training #CanGenAnalysis23 with presentations by participants! All teams had to analyse TCGA data from different #cancer types and present its drivers, oncoplots, mutational signatures and clinical correlations. I think it was a success! 😀😀

Yesterday after we closed the Wellcome Connecting Science Learning and Training #CanGenAnalysis23 we had a team dance competition...

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations dlvr.it/Szpq6r

congrats Paolo A. Ascierto a landmark paper illuminating the way for BRAF therapy in #melanoma #immunotherapy Nature Communications A must read !!! nature.com/articles/s4146…

Believe it or not this is what "well" looks like 🙈

Just hand me that deck of cards 😂

RUUUNN!!!

"I think we are close to submitting"

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications Clinical Cancer Research doi.org/10.1158/1078-0… 👉Distribution of 5 tissue-agnostic targets with FDA approval among different cancer types : BRAFV600E, RET & NTRK fusions, TMBhigh & MSI ESMO - Eur. Oncology